New international society of pediatric oncology Boston ototoxicity grading scale for pediatric oncology: Still room for improvement

Journal of Clinical Oncology

Volumn 30, Issue 19, 2012, Pages 2303-2306

  Gurney, James G ^a   Bass, Johnnie K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

AUDITORY THRESHOLD; BONE CONDUCTION; CHILDHOOD CANCER; DISEASE SEVERITY; EDITORIAL; HEARING; HEARING LOSS; HUMAN; OTOTOXICITY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME;

HEARING LOSS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 84864018352     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.3187     Document Type: Editorial

References (36)

1. Adamson PC, Bagatell R, Balis FM, et al: Chapter 10: General principles of chemotherapy, in Pizzo PA, Poplack DG (eds): Principles and Practices of Pediatric Oncology (ed 6). Philadelphia, PA, Lippincott, Williams & Wilkins, 2011, pp 279-355
2. Knight KRG, Kraemer DF, Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588-8596, 2005 (Pubitemid 46211500)
3. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584, 2007
4. Kushner BH, Budnick AS, Kramer K, et al: Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417-422, 2006 (Pubitemid 44036572)
5. Fish JD, Grupp SA: Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 41:159-165, 2008 (Pubitemid 351188913)
6. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al: Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 52:637-643, 2009
7. Parsons SK, Neault MW, Lehmann LE, et al: Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669-674, 1998 (Pubitemid 28486365)
8. Punnett A, Bliss B, Dupuis LL, et al: Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study. Pediatr Blood Cancer 42:598-603, 2004 (Pubitemid 38669747)
9. Bertolini P, Lassalle M, Mercier G, et al: Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649-655, 2004 (Pubitemid 39350398)
10. Biro K, Noszek L, Prekopp P, et al: Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 70:177-184, 2006 (Pubitemid 44154691)
11. Blakley BW, Cohen JI, Doolittle ND, et al: Strategies for prevention of toxicity caused by platinum-based chemotherapy: Review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope 112:1997-2001, 2002 (Pubitemid 35283462)
12. Brock PR, Bellman SC, Yeomans EC, et al: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991
13. Al-Khatib T, Cohen N, Carret AS, et al: Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol 74:913-919, 2010
14. Li Y, Womer RB, Silber JH: Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 40:2445-2451, 2004 (Pubitemid 39424959)
15. Qaddoumi I, Bass JK, Wu J, et al: Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30:1034-1041, 2012
16. Laverdière C, Cheung NK, Kushner BH, et al: Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 45:324-332, 2005
17. Laverdière C, Gurney JG, Sklar CA: Late effects of treatment, in Cheung NK, Cohn SL (eds): Neuroblastoma. Berlin, Germany, Springer, 2005, pp 277-288
18. Gurney JG, Tersak JM, Ness KK, et al: Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 120:e1229-e1236, 2007 (Pubitemid 350085519)
19. Petrou S, McCann D, Law CM, et al: Health status and health-related quality of life preference-based outcomes of children who are aged 7 to 9 years and have bilateral permanent childhood hearing impairment. Pediatrics 120:1044-1052, 2007 (Pubitemid 350085538)
20. Wake M, Hughes EK, Poulakis Z, et al: Outcomes of children with mild-profound congenital hearing loss at 7 to 8 years: A population study. Ear Hear 25:1-8, 2004 (Pubitemid 38182600)
21. Bess FH, Dodd-Murphy J, Parker RA: Children with minimal sensorineural hearing loss: Prevalence, educational performance, and functional status. Ear Hear 19:339-354, 1998 (Pubitemid 28465218)
22. Davis JM, Elfenbein JL, Schum R, et al: Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord 51:53-62, 1986 (Pubitemid 16165644)
23. Brock PR, Knight KR, Freyer DR, et al: Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston Ototoxicity Scale. J Clin Oncol 30:2408-2417, 2012
24. National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/protocoldevelopment/electronic- applications/docs/ctcae-glossary.pdf
25. National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-8.5x11.pdf
26. American Speech-Language-Hearing Association: Audiologic management of individuals receiving cochleotoxic drug therapy guidelines, 1994. http://www.asha.org/docs/html/GL1994-00003.html
27. Fouladi M, Chintagumpala M, Ashley D, et al: Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26:3749-3755, 2008
28. Lewis MJ, DuBois SG, Fligor B, et al: Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52:387-391, 2009
29. Chang KW, Chinosornvatana N: Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788-1795, 2010
30. Chang KW: Clinically accurate assessment and grading of ototoxicity. Laryngoscope 121:2649-2657, 2011
31. Neuwelt EA, Brock P: Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28:1630-1632, 2010
32. Jereczek-Fossa BA, Zarowski A, Milani F, et al: Radiotherapy-induced ear toxicity. Cancer Treat Rev 29:417-430, 2003 (Pubitemid 37185108)
33. Low WK, Toh ST, Wee J, et al: Sensorineural hearing loss after radiotherapy and chemoradiotherapy: A single, blinded, randomized study. J Clin Oncol 24:1904-1909, 2006 (Pubitemid 46638990)
34. Ho WK, Wei WI, Kwong DL, et al: Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 21:547-553, 1999 (Pubitemid 29415160)
35. Hua C, Bass JK, Khan R, et al: Hearing loss after radiotherapy for pediatric brain tumors: Effect of cochlear dose. Int J Radiat Oncol Biol Phys 72:892-899, 2008
36. Williams GB, Kun LE, Thompson JW, et al: Hearing loss as a late complication of radiotherapy in children with brain tumors. Ann Otol Rhinol Laryngol 114:328-331, 2005 (Pubitemid 40529990)